CRP and COVID-19: The principal findings of this study found that the usage of ambavizumab-romicizumab could improve clinical outcomes in patients infected with the omicron variant, including reduced mortality rate, but increased the length of both ICU stay and ventilation duration; Furthermore, the Amubarvimab - romlusevimab therapy, CRP, Lactate, and PT-INR were associated with ICU mortality in patients with COVID‐19.